Moderna (MRNA) said Friday its trial for a trivalent vaccine against norovirus is currently on hold by the US Food and Drug Administration after a single adverse event report of a close of Guillain-Barre syndrome.
Investigation of the adverse event is currently underway, according to the company.
Moderna said it expects the clinical hold will not impact the efficacy readout timeline for the northern hemisphere trial as enrollment has already been completed.
Shares were up nearly 4% in recent trading.
Price: 33.07, Change: +1.15, Percent Change: +3.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。